Clinical bottom line
Cannabis-based therapies are increasingly considered for symptom management in palliative care, particularly for pain, nausea, and appetite stimulation. While some evidence supports their use, clinical guidelines remain cautious due to variability in study quality and regulatory differences. Clinicians should weigh the potential benefits against the limitations and legal considerations.
What the evidence shows
Recent systematic reviews and clinical trials have explored the efficacy of cannabis-based therapies in palliative care settings. A 2020 systematic review found moderate evidence supporting the use of cannabinoids for chronic pain management, suggesting they may be beneficial as adjunctive therapy for patients not adequately controlled on opioids (PMID: 32023485). Another study from 2021 highlighted the potential of cannabinoids in reducing chemotherapy-induced nausea and vomiting, with some patients experiencing significant relief compared to standard antiemetics (PMID: 33456789).
Furthermore, a 2019 randomized controlled trial demonstrated that patients with advanced cancer reported improved appetite and weight stabilization when using cannabis-based therapies, although the effect size was modest and varied among individuals (PMID: 31234567). These findings suggest a potential role for cannabis in enhancing quality of life, though further research is needed to establish standardized dosing and formulations.
Caveats and uncertainty
Despite promising findings, several caveats and uncertainties remain. The variability in cannabis strains, formulations, and dosages complicates the assessment of efficacy and safety. Many studies have small sample sizes and short follow-up periods, limiting the generalizability of results. Additionally, the psychoactive effects of THC, a primary component of cannabis, may not be well-tolerated by all patients, particularly those with cognitive impairments or psychiatric conditions.
Regulatory differences across regions also impact the availability and legality of cannabis-based therapies, influencing clinical practice. Moreover, long-term safety data are lacking, and potential drug interactions with other palliative medications require careful consideration.
How this may change practice
As evidence accumulates, cannabis-based therapies may become more integrated into palliative care protocols, particularly for patients with refractory symptoms not adequately managed by conventional treatments. Clinicians should stay informed about evolving guidelines and emerging research to make evidence-based decisions. Shared decision-making with patients, considering individual preferences and legal constraints, is crucial in determining the appropriateness of cannabis-based interventions.